Acromegaly is a rare condition that occurs when the pituitary gland produces excessive amounts of growth hormone, usually due to a non cancerous tumour called an adenoma. Managing this condition is critical because prolonged exposure to high growth hormone levels can lead to serious complications such as heart disease, type 2 diabetes, and joint problems. The primary goals of treatment are to normalize growth hormone and insulin like growth factor 1 levels, reduce the size of the pituitary tumour, and alleviate physical symptoms. In the UK, a combination of surgery, specialized medication, and radiotherapy is used to provide a comprehensive management plan tailored to the individual’s needs.
What We’ll Discuss in This Article
- The role of transsphenoidal surgery as the primary treatment.
- How somatostatin analogues work to block hormone production.
- The use of growth hormone receptor antagonists in managing the condition.
- When dopamine agonists are utilized for mixed pituitary tumours.
- The application of radiotherapy for persistent or aggressive growths.
- Long term monitoring and the importance of biochemical control.
Transsphenoidal Surgery and Tumour Removal
For the majority of patients in the UK, surgery is the first line of treatment for acromegaly. The objective is to remove the pituitary tumour as completely as possible, which often leads to an immediate and significant drop in growth hormone levels. The standard procedure is transsphenoidal surgery, where a neurosurgeon accesses the pituitary gland through the nose and the sphenoid sinus.
This minimally invasive approach is highly effective for microadenomas and many macroadenomas. If the tumour is small and well defined, surgery can often result in a permanent cure. However, if the tumour has invaded surrounding tissues like the cavernous sinuses, total removal may be challenging. Even in these cases, reducing the bulk of the tumour, a process called debulking, can make subsequent medical treatments more effective. The NHS guidelines on acromegaly indicate that surgery provides the best chance for rapid hormonal control.
Medical Therapy with Somatostatin Analogues
When surgery does not fully normalize hormone levels, or if surgery is not an option for the patient, medication becomes the primary management tool. The most used drugs are somatostatin analogues, such as octreotide and lanreotide. These medications mimic the action of somatostatin, a natural hormone in the body that inhibits the release of growth hormone from the pituitary gland.
Somatostatin analogues are typically administered as long-acting injections once every four weeks. They are highly effective at lowering both growth hormone and insulin like growth factor 1 levels and can also cause the pituitary tumour to shrink in some patients. Common side effects include digestive issues like nausea, bloating, or gallstones, which are usually manageable with clinical guidance. These medications are often a lifelong requirement for patients whose tumours cannot be surgically cured.
Growth Hormone Receptor Antagonists
For patients whose hormone levels remain high despite surgery and somatostatin analogues, a newer class of medication called growth hormone receptor antagonists may be used. The primary drug in this category is pegvisomant. Unlike other treatments that target the pituitary gland itself, pegvisomant works by blocking the action of growth hormone at the site of the body’s tissues, particularly in the liver.
By preventing growth hormone from binding to its receptors, pegvisomant effectively stops the production of insulin like growth factor 1, which is responsible for most of the physical changes in acromegaly. This medication is administered as a daily subcutaneous injection. While it does not shrink the pituitary tumour, it is exceptionally effective at normalizing insulin like growth factor 1 levels and improving symptoms like joint pain and swelling. Regular monitoring of liver function is a standard safety requirement for patients on this therapy.
Use of Dopamine Agonists
Dopamine agonists, such as cabergoline, are occasionally used in the treatment of acromegaly, particularly when the pituitary tumour secretes both growth hormone and prolactin. While these drugs are more commonly associated with prolactinomas, they can suppress growth hormone production in a subset of acromegaly patients.
Cabergoline is taken as an oral tablet once or twice a week, making it more convenient than daily or monthly injections. However, it is generally less potent than somatostatin analogues or pegvisomant for controlling growth hormone. It is often used as an “add-on” therapy in combination with other medications to achieve better biochemical control. Clinicians monitor patients for potential side effects, including mood changes or heart valve issues, during long term use.
Radiotherapy for Persistent Disease
Radiotherapy is typically reserved for patients whose acromegaly is not fully controlled by surgery and medication, or for those with particularly aggressive tumours. It involves using targeted high energy beams to destroy the remaining tumour cells and gradually reduce hormone secretion. In the UK, advanced techniques like stereotactic radiosurgery or Gamma Knife are used to deliver precise radiation while sparing healthy brain tissue.
The main challenge with radiotherapy is that its effects are very slow, often taking several years to fully normalize hormone levels. Patients must continue their medical therapy during this waiting period. A significant long-term risk of radiotherapy is hypopituitarism, where the radiation eventually causes the pituitary gland to stop producing other essential hormones, necessitating lifelong hormone replacement therapy.
Long Term Monitoring and Quality of Life
Managing acromegaly is a long-term commitment that requires regular follow up with an endocrine multi-disciplinary team. Patients undergo periodic blood tests to measure growth hormone and insulin like growth factor 1, as well as MRI scans to monitor the pituitary gland. The goal is “biochemical remission,” where hormone levels are within the normal range for the patient’s age and sex.
Beyond hormone levels, treatment also focuses on managing complications such as sleep apnoea, hypertension, and joint damage. Physiotherapy and lifestyle adjustments can significantly improve the quality of life for those living with the residual effects of the condition. The NICE clinical knowledge summaries provide the framework for this integrated approach to chronic acromegaly care in the UK.
Conclusion
Acromegaly is managed through a combination of surgery to remove the pituitary tumour and various medications to block or inhibit growth hormone production. While surgery offers the best chance for an immediate cure, long term medical therapies like somatostatin analogues and pegvisomant are essential for many patients to maintain healthy hormone levels. Radiotherapy remains a vital option for complex cases. Consistent monitoring is the key to preventing complications and ensuring long term well being. If you experience severe, sudden, or worsening symptoms such as a sudden severe headache or vision loss, call 999 immediately.
Will I have to take medication forever if I have acromegaly?
If surgery successfully removes the entire tumour and your hormone levels normalize, you may not need medication; however, many patients require long term therapy to keep levels in check.
How do I know if the treatment is working?
Your doctor will perform regular blood tests to check your insulin like growth factor 1 levels and may use MRI scans to see if the tumour is shrinking or stable.
Can acromegaly be cured?
Yes, many patients are effectively cured through surgery, especially if the tumour is caught while it is still a small microadenoma.
Does the facial swelling go away after treatment?
Swelling of the soft tissues, such as the hands and face, often improves significantly once growth hormone levels are controlled, though changes to the bone structure are permanent.
Are the injections for acromegaly painful?
Most patients tolerate the monthly somatostatin analogue injections well, although there may be some temporary discomfort or a small lump at the injection site.
Can I still work while undergoing treatment?
Most people can continue to work and maintain their daily activities, though you may need time off for surgery or to recover from specific symptoms like fatigue.
What happens if I don’t treat acromegaly?
Untreated acromegaly leads to a significant increase in the risk of heart failure, diabetes, and colon polyps, which is why active management is so important.
Authority Snapshot (E-E-A-T Block)
This article provides a medically accurate overview of the treatment pathways for acromegaly within the UK. It was written by the medical content team and reviewed by Dr. Rebecca Fernandez to ensure alignment with current clinical standards. The content is strictly based on NHS and NICE guidance for the management of growth hormone-secreting pituitary adenomas.
